アブストラクト
| Title | ホルモン受容体陽性・HER2陰性 転移性乳がん治療の最前線 |
|---|---|
| Subtitle | 特集 がんゲノム医療の現状と展望 がん診療の最前線〜ゲノム医療, 個別化治療, 臨床試験〜 |
| Authors | 原文堅 |
| Authors (kana) | |
| Organization | 愛知県がんセンター乳腺科 部長 |
| Journal | Pharma Medica |
| Volume | 41 |
| Number | 2 |
| Page | 93-98 |
| Year/Month | 2024 / 5 |
| Article | 報告 |
| Publisher | メディカルレビュー社 |
| Abstract | ホルモン受容体陽性(HR+)ヒト上皮成長因子受容体2陰性(HER2-)の転移性乳がん(mBC)においてサイクリン依存性キナーゼ(CDK)4/6阻害剤 + 内分泌療法併用療法は内分泌療法単剤と比較して無増悪生存期間(PFS), 全生存期間(OS)を延長することが示され, 標準治療として広く使用されている. しかし内因性または治療によって誘導された獲得耐性後の治療については多くのアンメットニーズが残されている. 耐性機序として主なものはESR1変異とPI3K/AKT/mTORシグナル経路の遺伝子異常である. 現在それぞれ新規薬剤として, 経口選択的エストロゲン受容体ダウンレギュレーター(SERD)やPI3K阻害薬(alpelisib, inavolisib), AKT阻害薬(capivasertib)などの開発が進み, 臨床試験による有効性のエビデンスが確立されつつある. また抗体薬物複合体(ADC)の開発が進み, トラスツズマブ デルクステカン(T-DXd)はHR+/HER2-low患者に対する, サシツズマブ ゴビテカン(SG)はHR+/HER2-患者に対する新たな治療オプションとなった. 本稿では, CDK4/6阻害薬と内分泌療法に対する耐性の機序に基づく, HR+/HER2-転移性乳がんの臨床開発中の新規薬剤について概説する. |
| Practice | 薬学 |
| Keywords | ホルモン受容体陽性, 転移性乳がん, サイクリン依存性キナーゼ4/6阻害剤, 内分泌抵抗性, 抗体薬物複合体 |
- 全文ダウンロード： 従量制、基本料金制の方共に913円(税込) です。
参考文献
- 1) 日本乳癌学会(編).乳癌診療ガイドライン(1)治療編2022年版.東京;金原出版:2022. p.165-72.
- 2) 日本乳癌学会(編).乳癌診療ガイドライン(1)治療編2022年版.東京;金原出版:2022. p.179-82.
- 3) Kalinsky K, Accordino MK, Chiuzan C, et al. A randomized, phase II trial of fulvestrant or exemestane with or without ribociclib after progression on anti-estrogen therapy plus cyclin-dependent kinase 4/6 inhibition (CDK4/6i) in patients (pts) with unresectable or hormone receptor-positive (HR+), HER2-negative metastatic breast cancer (MBC): MAINTAIN trial. J Clin Oncol. 2022;40(Suppl 17):LBA1004.
- 4) Mayer E, Ren Y, Wagle N, et al. Palbociclib after CDK 4/6i and endocrine therapy (PACE): a randomized phase II study of fulvestrant palbociclib, and Avelumab for Endocrine Pre-treated ER+/HER2- Metastatic Breast Cancer. Cancer Res. 2023;83:GS3-06.
- 5) Llombart-Cussac A, Harper-Wynne C, Perello A, et al. Second-line endocrine therapy (ET) with or without palbociclib (P) maintenance in patients (pts) with hormone receptor-positive (HR[+])/human epidermal growth factor receptor 2-negative (HER2[-]) advanced breast cancer (ABC): PALMIRA trial. J Clin Oncol. 2023;41(Suppl 16):Abstract 1001.
残りの16件を表示する
- 6) Berger F, Marce M, Delaloge S, et al. Randomised, open-label, multicentric phase III trial to evaluate the safety and efficacy of palbociclib in combination with endocrine therapy, guided by ESR1 mutation monitoring in oestrogen receptor-positive, HER2-negative metastatic breast cancer patients: study design of PADA-1. BMJ Open. 2022;12:e055821.
- 7) Bidard FC, Kaklamani VG, Neven P, et al. Elacestrant (oral selective estrogen receptor degrader) versus standard endocrine therapy for estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: results from the randomized phase III EMERALD Trial. J Clin Oncol. 2022;40:3246-56.
- 8) Bardia A, Bidard FC, Neven P, et al. EMERALD phase 3 trial of elacestrant versus standard of care endocrine therapy in patients with ER+/HER2-metastatic breast cancer: Updated results by duration of prior CDK4/6i in metastatic setting. Cancer Res. 2023;83(Suppl 5):GS3-01.
- 9) Oliveira M, Pominchuck D, Nowecki Z, et al. Camizestrant, a next generation oral SERD vs fulvestrant in post-menopausal women with advanced ER-positive HER2-negative breast cancer: Results of the randomized, multi-dose Phase 2 SERENA-2 trial. Cancer Res. 2023;83(Suppl 5):GS3-02.
- 10) Andre F, Ciruelos E, Rubovszky G, et al. Alpelisib for PIK3CA-mutated, hormone receptor-positive advanced breast cancer. N Engl J Med. 2019;380:1929-40.
- 11) Rugo HS, Lerebours F, Ciruelos E, et al. Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a Phase 2, multicentre, open-label, non-comparative study. Lancet Oncol. 2021;22:489-98.
- 12) Jhaveri K, Seock-Ah, I, Saura C, et al. Phase III study of inavolisib or placebo in combination with palbociclib and fulvestrant in patients with PIK3CA-mutant, hormone receptor-positive, HER2-negative locally advanced or metastatic breast cancer: INAVO120 primary analysis. 2023 San Antonio Breast Cancer Symposium. Abstract GS03-13.
- 13) Turner NC, Oliveira M, Howell SJ, et al. Capivasertib in hormone receptor-positive advanced breast cancer. N Engl J Med. 2023;388:2058-70.
- 14) Modi S, Jacot W, Yamashita T, et al. Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer. N Engl J Med. 2022;387:9-20.
- 15) Harbeck N, Modi S, Jacot W, et al. Trastuzumab deruxtecan vs treatment of physician's choice in patients with HER2-low unresectable and/or metastatic breast cancer: subgroup analyses from DESTINY-Breast04. Cancer Res. 2023;83(Suppl 5):P1-11-01.
- 16) Ueno NT, Jacot W, Yamashita T, et al. Patient-reported outcomes (PROs) from DESTINY-Breast04, a randomized phase III study of trastuzumab deruxtecan (T-DXd) vs treatment of physician's choice (TPC) in patients (pts) with HER2-low metastatic breast cancer (MBC). Ann Oncol. 2022;33:S632-3.
- 17) Rugo HS, Bardia A, Marme F, et al. Sacituzumab Govitecan in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer. J Clin Oncol. 2022;40:3365-76.
- 18) Rugo HS, Bardia A, Marme F, et al. Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial. Lancet. 2023;402:1423-33.
- 19) Rugo H, Bardia A, Marme F, et al. Sacituzumab govitecan (SG) vs treatment of physician's choice (TPC): efficacy by Trop-2 expression in the TROPiCS-02 study of patients (pts) with HR+/HER2-metastatic breast cancer (mBC). Cancer Res. 2023;83(Suppl 5):GS1-11.
- 20) Schmid P, Cortes J, Marme F, et al. Sacituzumab govitecan (SG) efficacy in hormone receptor-positive/human epidermal growth factor 2-negative (HR+/HER2-) metastatic breast cancer (MBC) by HER2 immunohistochemistry (IHC) status in the phase 3 TROPiCS-02 study. Ann Oncol. 2022;33:S635-6.
- 21) Bardia A, Jhaveri K, Im S-A, et al. Datopotamab deruxtecan (Dato-DXd) vs chemotherapy in previously-treated inoperable or metastatic hormone receptor-positive, HER2-negative (HR+/HER2-) breast cancer (BC): Primary results from the randomised phase III TROPION-Breast01 trial. Ann Oncol. 2023;34(Suppl 2):S1264-5.
